Krystal Biotech, Inc. (KRYS) Q2 2022 Earnings Results

Krystal Biotech Misses on EPS, Stock Up 0.38%

Krystal Biotech's earnings report showed a larger-than-expected loss per share, which typically raises concerns among investors. However, the stock reacted positively, increasing by 0.38%. This could indicate that investors are optimistic about the company's future potential despite the current financial results.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-1.10	N/A	-1.85%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Management remains focused on advancing their pipeline and emphasized the importance of upcoming clinical trials. They acknowledged the current financial results but are optimistic about future opportunities.

Management highlighted ongoing efforts in product development.

They expressed confidence in long-term growth despite current challenges.

Krystal Biotech Misses on EPS, Stock Up 0.38%

Key numbers

Management commentary

Krystal Biotech, Inc.

More earnings this week

Krystal Biotech Misses on EPS, Stock Up 0.38%

Key numbers

Management commentary